Literature DB >> 12920695

Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica.

Miguel A González-Gay1, Mahsa M Amoli, Carlos Garcia-Porrua, William E r Ollier.   

Abstract

BACKGROUND AND OBJECTIVES: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are common and often overlapping diseases that generally occur in elderly patients. In this article, we examine the role of different genes as markers of disease susceptibility and severity in GCA and PMR.
METHODS: The influence of human leukocyte antigen (HLA)-DRB1 and tumor necrosis factor alleles, as well as the different allelic polymorphisms, on the susceptibility and severity to GCA and PMR was examined. A review of the literature was conducted.
RESULTS: Most studies have described an association of GCA with HLA-DRB1(*)04 alleles. However, HLA-DRB1 association in patients with PMR varies from one population to another. In Northwest Spain, patients with GCA and PMR exhibited different tumor necrosis factor microsatellite polymorphism associations. Studies of intercellular adhesion molecule-1 biallelic polymorphisms have yielded contradictory results. Interleukin 1 cluster and tumor necrosis factor alpha polymorphisms increased susceptibility to GCA and PMR slightly. In Northwest Spain, interleukin 6 promoter polymorphism at position -174 modulated the phenotypic expression of PMR in biopsy-proven GCA. In the same population, regulated upon activation, normal T cell expressed and presumably secreted gene promoter biallelic polymorphism at position -403 was a marker for PMR susceptibility but not for GCA, and corticotropin-releasing hormone polymorphism appeared to be implicated in the risk of severe ischemic complications in patients with GCA.
CONCLUSIONS: The present analysis confirms that GCA and PMR are polygenic diseases. The search for additional genes is necessary to better understand the pathogenesis of these conditions. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920695     DOI: 10.1053/sarh.2002.50025

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  28 in total

Review 1.  Giant cell arteritis: epidemiology, diagnosis, and management.

Authors:  Miguel A Gonzalez-Gay; Cristina Martinez-Dubois; Mario Agudo; Orlando Pompei; Ricardo Blanco; Javier Llorca
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

Review 2.  [Polymyalgia rheumatica: myalgic syndrome or occult vasculitis?].

Authors:  B Hellmich; W L Gross
Journal:  Internist (Berl)       Date:  2005-11       Impact factor: 0.743

Review 3.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 4.  Giant cell arteritis: diagnosis and therapeutic management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

Review 5.  CD24: from a Hematopoietic Differentiation Antigen to a Genetic Risk Factor for Multiple Autoimmune Diseases.

Authors:  Yixin Tan; Ming Zhao; Bo Xiang; Christopher Chang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

6.  Epidemiology of giant cell arteritis in an Arab population: a 22-year study.

Authors:  Neil R Miller
Journal:  Br J Ophthalmol       Date:  2007-06       Impact factor: 4.638

Review 7.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 8.  Diagnosis and treatment of giant cell arteritis.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Michele Bertoni; Carlo Salvarani
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

9.  [The genetics of vasculitides].

Authors:  J U Holle; S Wieczorek; J T Epplen; W L Gross
Journal:  Z Rheumatol       Date:  2011-04       Impact factor: 1.372

10.  Association between IL-18 gene polymorphisms and biopsy-proven giant cell arteritis.

Authors:  Rogelio J Palomino-Morales; Tomas R Vazquez-Rodriguez; Orlando Torres; Inmaculada C Morado; Santos Castañeda; Jose A Miranda-Filloy; Jose L Callejas-Rubio; Benjamin Fernandez-Gutierrez; Miguel A Gonzalez-Gay; Javier Martin
Journal:  Arthritis Res Ther       Date:  2010-03-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.